UroGen Pharma Ltd. (URGN) vs Vir Biotechnology, Inc. (VIR)
A side-by-side comparison of UroGen Pharma Ltd. and Vir Biotechnology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
URGN
UroGen Pharma Ltd.
$41.43HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
VIR
Vir Biotechnology, Inc.
$11.60HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — URGN vs VIR
growth of $100 · dividends reinvested · last 7yURGN +102.7% (+10.6%/yr)VIR -16.0% (-2.5%/yr)URGN compounded faster over this window
URGN VIR
URGN vs VIR: by the numbers
- •URGN is the larger company ($2.02B vs $1.96B market cap).
- •Both run net losses; URGN's is the smaller (-51.73% vs -83.00% net margin).
- •URGN grew revenue faster over the past five years (42.66% vs 11.22% CAGR).
Metrics side by side
Valuation
| Metric | URGN | VIR |
|---|---|---|
| P/S ratio | 10.70 | 6.45 |
| P/B ratio | N/A | 1.99 |
Profitability
| Metric | URGN | VIR |
|---|---|---|
| Gross margin | 90.85% | 82.92% |
| Operating margin | -113.73% | -682.68% |
| Net margin | -51.73% | -83.00% |
| ROE | N/A | -25.62% |
| ROIC | -34.96% | -24.09% |
Growth (annualized)
| Metric | URGN | VIR |
|---|---|---|
| Revenue CAGR (5Y) | 42.66% | 11.22% |
| Total return CAGR (5Y) | 20.32% | -19.71% |
Frequently asked
- Which has grown faster, URGN or VIR?
- Over the past five years, URGN grew revenue faster — URGN at a 42.66% CAGR versus VIR at 11.22%.
- How have URGN and VIR total returns compared?
- Over the past 5 years, URGN delivered 20.32% and VIR delivered -19.71% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
UroGen Pharma ROEVir Biotechnology ROEUroGen Pharma operating marginVir Biotechnology operating marginUroGen Pharma revenue growthVir Biotechnology revenue growthUroGen Pharma free cash flowVir Biotechnology free cash flow
UroGen Pharma & Vir Biotechnology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.